DexCom Inc (DXCM)vsElectromed Inc (ELMD)
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
ELMD
Electromed Inc
$27.25
+2.25%
HEALTHCARE · Cap: $226.72M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 6636% more annual revenue ($4.97B vs $73.78M). DXCM leads profitability with a 20.1% profit margin vs 15.3%. ELMD appears more attractively valued with a PEG of 0.35. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
ELMD
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXCM.
Margin of Safety
-55.2%
Fair Value
$16.28
Current Price
$27.25
$10.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Growing faster than its price suggests
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 21 in profit
Earnings expanding 49.0% YoY
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.9x book value
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : ELMD
The strongest argument for ELMD centers on PEG Ratio, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 19.7%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : ELMD
The primary concerns for ELMD are Market Cap.
Key Dynamics to Monitor
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DXCM scores higher overall (74/100 vs 70/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Electromed Inc
HEALTHCARE · MEDICAL DEVICES · USA
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?